Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
The Schall Law Firm Starts Inquiry Into Accusations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Communicate
11:00am, Saturday, 06'th Jul 2024
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
Swing Trading Regeneron Stock Shows How To Bob And Weave
03:56pm, Friday, 05'th Jul 2024
What do boxers and swing traders have in common? Avoiding big hits and striking at opportunities when they come.
LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
12:00pm, Friday, 05'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors
7 High Priced Stocks That Would Benefit From a Stock Split
03:45pm, Thursday, 04'th Jul 2024
Several high-profile stock splits have occurred recently. First, Nvidia (NASDAQ: NVDA ) decided to implement a 10-for-1 stock split which took effect June 10.
LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
09:10am, Wednesday, 03'rd Jul 2024
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
01:00am, Wednesday, 03'rd Jul 2024
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
01:00am, Wednesday, 03'rd Jul 2024
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two l
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmace
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
12:53pm, Tuesday, 02'nd Jul 2024
NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) br
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
10:15am, Tuesday, 02'nd Jul 2024
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
05:16am, Tuesday, 02'nd Jul 2024
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN
11:51am, Sunday, 30'th Jun 2024
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Suc
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmac
